Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Sep;93(9):3499-504.
doi: 10.1210/jc.2008-0828. Epub 2008 Jul 1.

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

Virginia A Triant  1 , Todd T Brown, Hang Lee, Steven K Grinspoon
Affiliations
Comparative Study

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

Virginia A Triant et al. J Clin Endocrinol Metab. 2008 Sep.

Abstract

Context: Reduced bone mineral density has been demonstrated among HIV-infected patients, but fracture prevalence is unknown.

Objective: The objective of the study was to compare fracture prevalence in HIV-infected and non-HIV-infected patients.

Design: This was a population-based study.

Setting: The study was conducted at a large U.S. health care system.

Patients: A total of 8525 HIV-infected and 2,208,792 non-HIV-infected patients with at least one inpatient or outpatient encounter between October 1, 1996, and March 21, 2008, was compared.

Main outcome measure: Fracture prevalence using specific International Classification of Diseases, Ninth Revision, Clinical Modification fracture codes was measured.

Results: The overall fracture prevalence was 2.87 vs. 1.77 patients with fractures per 100 persons in HIV-infected, compared with non-HIV-infected patients (P < 0.0001). Among females, the overall fracture prevalence was 2.49 vs. 1.72 per 100 persons in HIV-infected vs. non-HIV-infected patients (P = 0.002). HIV-infected females had a higher prevalence of vertebral (0.81 vs. 0.45; P = 0.01) and wrist (1.31 vs. 0.83; P = 0.01) fractures per 100 persons, compared with non-HIV-infected females but had a similar prevalence of hip fractures (0.47 vs. 0.56; P = 0.53). Among males, the fracture prevalence per 100 persons was higher in HIV-infected vs. non-HIV-infected patients for any fracture (3.08 vs. 1.83; P < 0.0001), vertebral fractures (1.03 vs. 0.49; P < 0.0001), hip fractures (0.79 vs. 0.45; P = 0.001), and wrist fractures (1.46 vs. 0.99; P = 0.001). Fracture prevalence was higher relative to non-HIV-infected patients among African-American and Caucasian females and Caucasian males.

Conclusions: Fracture prevalence is increased in HIV-infected compared with non-HIV-infected patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Fracture prevalence comparing HIV-infected and non-HIV-infected patients by gender and site of fracture, age group, and race. Panels A, C, and E represent females. Panels B, D, and F represent males. A and B, Comparison of fracture prevalence in HIV-infected vs. non-HIV-infected patients according to gender and site of fracture. C and D, Comparison of fracture prevalence in HIV-infected vs. non-HIV-infected patients according to gender and age group. E and F, Comparison of fracture prevalence in HIV-infected vs. non-HIV-infected patients according to gender and race. Light bars and lines represent HIV-infected patients; dark bars and lines represent non-HIV-infected patients. In C and D, the P values are for the comparison of overall fracture prevalence between HIV-infected and non-HIV-infected patients.
See this image and copyright information in PMC

References

    1. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE 2000 Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63–F67 - PMC - PubMed
    1. Carr A, Miller J, Eisman JA, Cooper DA 2001 Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 15:703–709 - PubMed
    1. Gold J, Pocock N, Li Y 2002 Bone mineral density abnormalities in patients with HIV infection. J Acquir Immune Defic Syndr 30:131–132 - PubMed
    1. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M, Tebas P 2003 Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482–490 - PubMed
    1. Bongiovanni M, Fausto A, Cicconi P, Menicagli L, Melzi S, Ligabo VE, Cornalba G, Bini T, Sardanelli F, Monforte AD 2005 Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretroviral therapy and HIV itself? J Acquir Immune Defic Syndr 40:503–504 - PubMed

Publication types